Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

TransMedics Group, Inc. Common Stock

TMDX

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Last trade $94.79
Day change +$2.58 (+2.80%)
Day range $90.57 – $95.76
Volume 525,118
Market cap $3.20B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.2B
Price / earnings
22.17×
Price / book
5.82×
Price / sales
4.4×
EV / sales
4.91×
EV / EBITDA
28.15×

Profitability

Earnings per share
$4.16
Return on assets
9.52%
Return on equity
26.23%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.56×
Current ratio
4.53×
Quick ratio
4.15×
Cash ratio
3.22×

Cash flow

Price / cash flow
28.51×
Price / free cash flow
71.66×
Free cash flow
$44.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TMDX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$203.01M$189.95M$173.93M$160.76M$143.82M$157.37M$143.54M$121.62M
Cost of revenue$84.35M$76.75M$72.77M$67.35M$59.25M$60.78M$55.31M$49.61M
Gross profit$118.66M$113.2M$101.16M$93.41M$84.58M$96.59M$88.23M$72.01M
Selling, general and administrative$61.33M$57.83M$62.99M$51.44M$46.02M$44.09M$43.63M$46.91M
Research and development$29.18M$31.63M$24.88M$20.7M$15.26M$15.93M$17.16M$16.46M
Total operating expenses$90.52M$89.46M$87.86M$72.14M$61.28M$60.02M$60.79M$63.37M
Operating income$28.14M$23.74M$13.3M$21.27M$23.3M$36.57M$27.44M$8.64M
Interest expense-$7.27M-$7.23M-$7.17M-$3.35M-$3.49M-$3.48M-$3.46M-$3.57M
Income before taxes$24.1M$19.41M$8.49M$21.63M$23.03M$36.18M$26.68M$6.99M
Income taxes$7.03M$4.72M$1.17M-$83.75M-$1.29M$1.28M$994K$132K
Net income$17.07M$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M
Net income attributable to common shareholders$17.07M$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M
EBITDA$38.98M$33.98M$25.16M$28.74M$30.15M$43.3M$33.58M$14.32M
Basic earnings per share$0.49$0.42$0.21$3.08$0.71$1.03$0.76$0.20
Diluted earnings per share$0.46$0.41$0.20$2.57$0.66$0.92$0.70$0.19

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

TransMedics reported Q3 2026 revenue of $203.01 million, up 41.2% year-over-year, beating the consensus estimate of $181.81 million by 11.66%. EPS came in at $0.51, delivering an 88.89% surprise versus the $0.27 consensus estimate. Key metrics showed strong performance across most segments, particularly in international markets and service revenue. However, the stock has declined 10.3% over the past month and carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics (TMDX) is positioned for growth driven by its innovative Organ Care System (OCS) technology and pipeline expansion, including Gen 3.0 platform and international expansion. However, the company faces headwinds from declining gross margins (down 180 basis points to 59.6%) and reduced 2026 operating margin guidance, as it prioritizes revenue growth over near-term profitability.

GlobeNewswire Inc.

TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet

TransMedics has selected Gogo Galileo to provide high-performance connectivity across its fleet of 22 Embraer Phenom 300E aircraft used for time-critical organ transport missions. The Gogo Galileo HDX system, powered by Eutelsat OneWeb's LEO satellite network, will be installed on all aircraft by 2027, making TransMedics the first organ transplant company to achieve full fleet connectivity. The system will enable real-time monitoring of organs during transport with enhanced cybersecurity and redundancy features.

Zacks Investment Research

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.